ARCH Venture Partners wraps up 12th fund at nearly $3bn

ARCH Venture Fund XII will back early-stage biotech companies.

  • The firm’s prior fund closed on $1.9 billion in January 2021
  • New capital will go to investments in early-stage biotech companies
  • ARCH was founded in 1986

ARCH Venture Partners has closed its 12th fund at just under $3 billion. ARCH Venture Fund XII will back early-stage biotech companies.

The venture firm’s previous fund closed at $1.9 billion in January 2021.

“With over 35 years of venture experience, ARCH has been creating and consolidating companies for the long term,” ARCH Co-founder and managing director Robert Nelsen said in a statement. “We would like to thank our limited partners for supporting our 12th fund.”

ARCH did not disclose the names of LPs in the new fund. Investors in prior funds include Alaska Permanent Fund, Allstate Insurance Co, California Pubic Employees’ Retirement System, New Mexico State Investment Council and Wellcome Trust, according to PitchBook.

Based in Chicago, ARCH Venture Partners was founded in 1986. It invests in healthcare, information technology, and commercial services companies.